Lung Cancer

After a 10-year battle with cancer, the beloved actress, wife, mother and advocate passed away at 80.

Traveling helped me remove myself from the storyline of cancer and reconnect with the world around me.

Here’s a sneak peek at what’s inside our Summer 2019 issue.

Hossein Borghaei, Fox Chase Cancer Center - a physician in the field of cancer care - discusses his experiences treating patients with non-small cell lung cancer and why recent data is now available and could have a positive impact on the treatment landscape. 

The American Lung Association’s chief medical officer discusses e-cigarette use and answers common questions surrounding this increasing epidemic.

Patients whose cancers have the NTRK gene fusion as well as those with ROS1-positive non-small cell lung cancer now have a second targeted therapy as a treatment option.

When non-small cell lung cancer spreads to just a few sites, therapy can be given with curative intent – and immunotherapy can help delay relapse.

Collecting data about cancer through registries can help experts detect trends and patterns, leading to better care for patients.

The Food and Drug Administration approved Rozlytrek (entrectinib) for adult and adolescent patients 12 years of age and older whose cancers have the NTRK gene fusion and for adults with non-small cell lung cancer whose tumors are ROS1-positive and have spread to other parts of the body.

The earlier lung cancer is detected, the better chance a person has of surviving the disease. Knowing the risk factors and statistics will help you to understand how you can minimize your possibility of developing the disease.